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Abstract
Conducting research to identify modifiable risk factors for birth defects is difficult for a variety of 
reasons. While some challenges are familiar to researchers across many disciplines, the confluence 
of issues affecting birth defects research may not be well understood by those outside of the field. 
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This article describes several methodological challenges to the study of birth defects and ways 
these challenges might be addressed: (1) ascertainment, definition and classification of birth 
defects; (2) exposure assessment on modifiable risk factors; (3) analytical challenges related to 
small numbers and multiple statistical tests; (4) the role of genetics, including the collection of 
specimens and analysis of genetic data; and (5) challenges in translating research and 
demonstrating public health impact. Understanding these issues is important for researchers 
planning studies, reviewers evaluating the scientific merit of results from these studies, and 
consumers of the research, including fellow researchers, policy makers, health care providers, and 
families.
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Introduction
Birth defects are common, costly, and critical. Although individual birth defects may be 
rare, collectively about three percent of U.S. births are affected by a major structural or 
chromosomal birth defect [1]. Hospital costs for birth defects in the year 2004 were $2.6 
billion [2]; the physical and emotional cost of birth defects, while difficult to quantify, are 
also high. Birth defects can lead to lifelong disability and are the leading cause of infant 
mortality in the United States.[3].
Although genetic factors contribute to birth defects risk, environmental (i.e., non-genetic) 
factors influence the risk for birth defects as well. Some of these environmental risk factors 
are recognized as strong teratogens, such as maternal rubella infection [4] and use of the 
medications thalidomide or isotretinoin during pregnancy [5]. Identification of 
environmental teratogens provides an opportunity for prevention activities. Maternal folic 
acid intake during the periconceptional period is one of the most successful examples of an 
intervention to prevent birth defects. Randomized controlled trials demonstrated the role of 
folic acid in preventing neural tube defects (NTDs) [6, 7] and a 26 percent decrease in the 
birth prevalence of NTDs was observed in the United States after folic acid fortification of 
enriched cereal grain products, which was mandated in the late 1990s [8]. It has been 
estimated, however, that among pregnancies affected by birth defects the cause is unknown 
for two-thirds [9], and in these instances there is no clear opportunity for prevention. 
Therefore, continued efforts to identify modifiable risk factors for birth defects are 
important.
Conducting research to identify modifiable risk factors for birth defects is difficult, however, 
for a variety of reasons. While some challenges are familiar to researchers across many 
disciplines, other issues affecting birth defects research may not be well understood by those 
outside of the field. This article describes several methodological challenges to the study of 
birth defects and ways these challenges might be addressed.
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Ascertainment, Definition, and Classification of Birth Defect Cases
Case ascertainment
Studies of modifiable risk factors for birth defects often rely on data from population-based 
surveillance systems to identify cases. The surveillance systems should capture birth defects 
occurring among multiple pregnancy outcomes (i.e., live births, stillbirths, pregnancy 
terminations) and studies should include cases from all of these outcomes. The distribution 
of pregnancy outcomes varies widely across different birth defects; the prevalence of birth 
defects for which termination or stillbirth are more common pregnancy outcomes can be 
substantially underestimated if only live births are ascertained. Results from studies based 
only on live births can be biased if the risk factor of interest is related to the stillbirth or 
termination risk in birth defect cases; there will be an under-ascertainment of cases (and an 
under-estimate of the true association) in a design that is limited to live births [10]. If the 
surveillance system uses either active case ascertainment (characterized by case finding and 
medical record abstraction, in addition to abstraction of passively reported cases, and 
clinical review), or passive case ascertainment with added clinical review and verification 
using administrative information (e.g., hospital discharge codes), the data will likely be of 
higher quality than exclusively passive systems with limited data sources, which often have 
over-ascertainment of some subtypes of birth defects, and under-ascertainment of others.
The rarity of individual birth defects makes the case-control methodology an efficient option 
for research. However, cohorts have also been assembled through extensive, longitudinal 
linkages of national registries, such as the Nordic Perinatal Bereavement Cohort [11], and 
large pregnancy follow-up studies, such as the Norwegian Mother and Child Cohort Study 
(MoBa) [12, 13]. In the United States, the Collaborative Perinatal Project has been an 
influential cohort, albeit with limited numbers for assessing risk factors for rare conditions 
such as structural birth defects [14, 15]. There have been recent attempts to simulate 
population-based cohorts for birth defects research in the United States using large data 
linkage collaborations across several health maintenance organizations, such as the 
Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) [16]; these linked 
data capture clinical information recorded in electronic medical records, as well as 
prescription drug claims.
Case definition and classification
The concepts of case definition and case classification are often interwoven and difficult to 
completely tease apart. A case definition is a uniform set of criteria used to decide whether 
an infant or fetus has a birth defect that will be included in a study; it is intended to increase 
the likelihood that included cases have the defect of interest. Case definitions are typically 
developed before a study begins and will include components such as age at diagnosis and 
method of diagnosis, although these may not be straightforward (e.g., which defects to 
include based on prenatal ultrasound only) [17]. Epidemiologic studies typically include 
only birth defects considered major (e.g., open spina bifida, but not spina bifida occulta 
[18]). Some minor defects may represent the milder end of a spectrum and thus have the 
same risk factors as corresponding major defects; however, there is evidence that minor 
defects are inconsistently ascertained [19], so exclusion criteria for minor defects should be 
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established as part of the case definition [20]. Defects may also be excluded based on known 
pathogenesis of the defect. For example, in a risk factor study for clubfoot, the case 
definition would typically exclude individuals with both clubfoot and spina bifida because 
the clubfoot is thought to be secondary to interruption of motor signals from the spinal cord 
(and thus diminished in utero movement of the extremity) and is not intrinsic to the foot. In 
general, reliance on International Classification of Diseases (ICD) codes as the only 
determinant of case status can lead to inappropriate inclusion or exclusion of cases [21, 22]. 
These codes may not be sufficiently specific to define an appropriate case group. For 
example, the ICD-9 code 745.5 encompasses both atrial septal defect (ASD) and patent 
foramen ovale (PFO); ASD is typically considered a major birth defect, while PFO is not 
[23, 24]. Further, differential diagnoses in the medical record to ‘rule out’ possible 
diagnoses may mistakenly be coded as final diagnoses. Use of verbatim descriptions of the 
diagnoses and results of clinical tests and procedures to determine individual case status is 
essential in overcoming many of these challenges [25].
Case classification includes grouping defects into meaningful categories for analysis. Case 
classification is important in risk factor studies because inclusion of infants with different 
underlying causes of their defect(s) may bias the magnitude of an observed association 
toward the null [26]. In some instances defect categories may be combined, which allows for 
larger case groups, if it is plausible that the defects share a common etiology. However, 
commonly grouped defects can have associated risk factors that are not shared. For example, 
although neural tube defects are often analyzed as a single defect category, different risk 
factors have been observed for anencephaly and spina bifida, the two primary defects 
included in this category [27]. Classifying individual congenital heart defects can be 
particularly challenging due to their complexity [28]. The issue of determining when to 
“lump” birth defects into a single category and when to “split” them out into different 
categories has long been a challenge of researchers [26, 29]. Although researchers should 
strive for homogeneity within their case groups, ultimately each case of a birth defect will 
have unique characteristics, and meaningful grouping of some type must occur in order to 
conduct analyses. Because of the overall heterogeneity of birth defects, analyses of “all birth 
defects” or even analyses by body system (e.g., cardiac, gastrointestinal) are unlikely to 
yield informative results.
Birth defects may occur in isolation or in combination with defects in other body systems, 
often referred to as multiple birth defects (or multiple congenital anomalies). Case 
classification also involves determining if an infant has the birth defect as an isolated 
occurrence, as part of multiple birth defects, or as a component of a syndrome (i.e., a 
recognizable pattern of defects that is known or presumed to have a specific cause, such as a 
single-gene disorder). Previous studies have identified that the etiology of isolated defects 
can differ from the etiology of multiple defects [30, 31]. Simply using the number of 
recognized defects to assign a case into a multiple birth defect category is not valid because 
infants can have one primary major birth defect with one or more secondary major defects as 
sequence events (e.g., spina bifida with clubfoot); can have more than one defect in a given 
body system (e.g., multiple cardiac defects), which may or may not be appropriate to 
analyze separately; or can have minor birth defects. With thoughtful programming, 
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classification by computer algorithms can be useful to identify infants with isolated birth 
defects or infants with some known syndromes; however, classification of infants with 
multiple birth defects, which can be a substantial proportion of cases, is best done by 
individual case review.
In risk factor studies, infants whose defects are consistent with syndromes of known 
etiology (e.g., single gene or chromosomal disorder) should probably be excluded. 
Identifying syndromic cases is challenging and often limited to excluding infants with 
existing syndrome diagnoses. Among infants with multiple defects, certain patterns may be 
identified (e.g., VATER association [32]) and these patterns can be assessed in relation to 
specific exposures, potentially leading to the identification of a previously-unrecognized 
syndrome or phenotype (e.g., embryopathy related to mycophenolate mofetil exposure [33]). 
Examination of patterns among birth defects associations can help in exploring the 
biological plausibility of findings. A related concept is the grouping of cases (with either 
isolated or multiple defects) by presumed pathogenic mechanisms (e.g., vascular etiology) 
when testing the association of particular birth defects with exposures that have known 
biologic effects (e.g., nicotine and vasoconstriction) [34, 35].
The lack of a standard process for defining and classifying birth defects has made 
comparisons of results across different epidemiologic studies difficult. To address these 
issues, researchers can agree on a set of standards and analyze their combined data 
accordingly. A successful example of this practice is the multi-site National Birth Defects 
Prevention Study (NBDPS), for which clinical geneticists and experts in pediatric 
cardiology have developed and published a system of case classification built upon previous 
efforts of others [36-38] to ensure homogeneous case groups [17, 39]. Adoption of standard 
case definitions and methods for case review and classification will facilitate replication of 
study findings in different study populations.
Exposure Assessment of Modifiable Risk Factors
Embryogenesis occurs in the first eight weeks of pregnancy and most birth defects develop 
in the first trimester [40]. Therefore, exposures during the first weeks of pregnancy are most 
relevant for assessing risk factors for birth defects. Accurately ascertaining early pregnancy 
exposures to modifiable risk factors is a fundamental challenge of birth defects research. It is 
difficult to identify women just before or in the first few weeks of pregnancy; in the United 
States, approximately half of pregnancies are unplanned [41] and many pregnancies are not 
recognized until the end of the first trimester [42]. Therefore, prospective data collection 
typically relies on healthcare databases. Examples of such databases include records from 
healthcare visits [43] and pharmacies [44]. Exposure data can also be collected 
retrospectively by asking the mother about her exposures during pregnancy after the 
pregnancy has ended.
There are many advantages of using healthcare databases to ascertain first trimester 
exposures: the data are routinely collected and thus can be more cost-efficient to use. Also, 
since the data are recorded prior to the diagnosis of a birth defect, these data are not subject 
to recall bias, which is often a concern with retrospective exposure ascertainment in a case-
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control study. A major challenge of using healthcare databases is that typically they are not 
designed for research but for administrative purposes; therefore, the types of information 
that are included may not be ideal for studies. Important information, such as smoking 
status, over-the-counter medication use or herbal use may not be available or might be 
inconsistently ascertained. Although healthcare records may contain information on 
prescribed or dispensed medications, they cannot confirm whether medications were taken, 
nor can they account for prescription medications that were taken without a prescription 
(e.g., borrowed or shared medication, a practice reported by over 1/3 of women [45]).
An advantage of retrospective data collection via maternal self-report is that it allows the 
mother to document her actual behaviors (e.g., whether she took a prescribed medication), 
which is important since many pregnant women change their behaviors (e.g., stop taking 
prescribed medication) once they learn they are pregnant [46]. A disadvantage of 
retrospective data collection is the potential for recall bias if mothers of affected children 
report their exposures differently than mothers of unaffected children [47, 48].
Some pregnancy exposure cohorts are based on a convenience sample, such as those derived 
from teratogen information services (TIS). Identifying a comparison group of women for 
analyses of exposures in TIS cohorts is challenging, since all women in their cohort have 
some exposure that caused them concern. Some TIS studies have used as controls pregnant 
women exposed to medications believed not to be teratogenic, those exposed to medications 
only in the 3rd trimester, or those with the same underlying condition but on a different 
medication [49]. Recent studies based on TIS cohorts, such as the MotherToBaby Pregnancy 
Studies conducted by the Organization of Teratology Information Specialists [50], included 
an expert clinician in-person examination of every baby born to a mother enrolled in the 
study; however, the potential for selection bias remains. Regulatory authorities encourage 
the creation of pregnancy exposure registries in order to detect signals of an increased risk of 
birth defects associated with use of specific medications, such as antiretroviral medications 
[51, 52] and medications used to treat epilepsy [53]. Registry participation is often 
voluntary, relying on healthcare providers to conduct follow-up and submit data [54]. 
Considerations for the establishment of optimal pregnancy registry studies have been 
previously published [55, 56].
Widespread use of electronic medical records provides an opportunity for improved research 
data. Electronic medical records may allow linkage of pregnancy information, pharmacy 
records, and maternal and fetal outcomes, but will still be limited by the completeness and 
accuracy of the information entered, which can vary widely [57]. These data would be even 
more valuable if pregnant women were asked a brief set of standardized questions regarding 
their exposures immediately before and throughout their pregnancies.
Analytical Issues
Statistical Power
Perhaps the most challenging analytical issue facing birth defects researchers is that of 
statistical power to detect associations. Using traditional frequentist statistical methods, the 
power of a study to detect a true difference in the prevalences of a birth defect among two 
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different exposure groups is dependent on several factors: the p-value cut-point chosen to 
define statistical significance (conventionally p<0.05), the strength of the association 
between the exposure and the defect, and the prevalence of the exposure in the population 
[58]. For a given sample size, stronger associations and associations with more common 
exposures are easier to detect.
Despite the concern of recall bias, case-control studies are commonly employed to study 
birth defects. Consider one of the most common birth defects, cleft lip with or without cleft 
palate, with an estimated birth prevalence of 10.9/10,000 live births [59]. Given that two-
thirds of U.S. pregnancies result in a live birth [60], over 15,000 pregnant women would 
have to be followed from the beginning of their pregnancies in order to obtain prospective 
information on pregnancy exposures for 11 cases. For a rarer defect, such as encephalocele, 
which has a prevalence of 0.8/10,000 live births [59], almost 19,000 pregnant women would 
need to be followed to obtain data on one case. National data repositories and healthcare 
databases have allowed some prospective risk factor studies for birth defects [61-63], but 
even using many years of nationwide data results in low statistical power for some defects. 
Even a case-control design cannot entirely circumvent sample size issues, as accumulating 
sufficient case numbers can take years, especially in population-based settings.
In addition to individual birth defects being rare, some modifiable risk factors are relatively 
rare. For example, maternal pregestational diabetes is strongly associated with certain birth 
defects [30]; however, the prevalence of pregestational diabetes among mothers of infants 
not affected by a major birth defect is less than 1% [30]. And although medication use 
among pregnant women is highly prevalent [48, 64, 65], the use of individual medications 
can be rare [66]. Similar medications can sometimes be grouped together to help increase 
exposure prevalence, but there is the potential for different effects even among medications 
within a single class [67], and this type of grouping does not provide information on which 
medications within a class might be better alternatives for use during pregnancy.
Multiple Testing
In order to conduct comprehensive assessments of particular prenatal exposures, exposures 
are often assessed in relation to multiple birth defect categories in a single study. This 
practice can lead to difficulty in interpreting results in the context of multiple testing [68]. 
Although publications from a given study may report individual exposures or defects, the 
collection of analyses amount to many tests of statistical significance being conducted on a 
single sample. Using standard frequentist statistical conventions, five percent of the 
associations tested are expected to be statistically significant due to chance, rather than a 
true association. While the potential for a type I error (rejecting a true null hypothesis) due 
to multiple testing may be relatively easy to identify in a single publication, it is more 
difficult to appreciate this potential when the tests are spread across many publications, yet 
the potential for observing a spurious association remains.
Conventional methods are available to reduce the likelihood of a type I error, including the 
Bonferroni method, in which the alpha level for individual statistical tests is reduced such 
that there is a 5 percent collective probability of a type I error across all tests, rather than for 
each individual test. Although this method is routinely used in genetic discovery analyses, 
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the p-values and resulting confidence intervals are considered too conservative for most 
epidemiologic studies of non-genetic exposures, and unreasonably increase the probability 
of a type II error (failing to reject a false null hypothesis) [47]. Further, if the tests are spread 
out over multiple analyses, some of which have yet to be conducted, there is no practical 
way to estimate how many statistical tests will ultimately be conducted on a single dataset.
Bayesian statistical methods offer the opportunity to address the issues of both multiple 
testing and small numbers, through the use of prior knowledge and multilevel models [47, 
69]. Bayesian methods, which are beyond the scope of this article, focus on quantifying 
uncertainty rather than relying on the concept of repeating hypothetical studies. Bayesian 
methods are increasingly being used in birth defects research, including analyses of 
antihistamine medication exposures [70]; antiepileptic medication exposures [71]; and 
maternal occupation [72].
The Role of Genetics
The role of genetics in public health is to facilitate identification of populations most 
susceptible to disease and the underlying biological mechanisms that are affected by 
modifiable risk factors. Identification of modifiable risk factors may be obscured without 
stratifying by genetic variation, including variation in the epigenome (heritable chemical 
modifications to the genome that result in changes in gene expression without changing the 
underlying DNA sequence) [73, 74]. However, inclusion of a genetic component in an 
epidemiologic study increases its complexity – additional factors that must be considered 
include specimen collection, including timing and quality; allele frequencies and effect 
sizes; assay design and quality; specimen and data storage; and ethical, legal, and social 
implications.
Some specific challenges in collecting and analyzing genetic and epigenetic data for birth 
defects research include small sample sizes that often preclude high density variant studies 
and limit research to only the largest racial-ethnic groups, even in multi-site studies [75], 
and maternally-mediated genetic and epigenetic effects acting on the fetus during gestation 
which require more complex analytical methods and, ideally, collection of specimens during 
the relevant embryological period.
Blood samples are the ‘gold standard’ for genetic material, but specimen quality must be 
balanced with achieving a reasonable response rate. Convenient non-invasive collection 
methods are preferred, especially in pediatric populations [76, 77]. Distrust of genetic 
research, especially among minorities, hampers sample collection and could create selection 
bias [76, 78-80]. Rapid advances in technology and implementation of data sharing policies 
were not anticipated in the initial consent of many studies and raise the risk of identifying 
study participants from coded genetic data. The evolving landscape will undoubtedly yield 
important clues in causes of birth defects, but raise additional ethical issues with pediatric 
populations, such as returning individual results to parents of minors, ensuring individual 
genetic data confidentiality, and use of data as children reach the age of majority [81-84].
Genetic factors undoubtedly play a crucial role in the development of a number of different 
birth defects. The challenges of obtaining enough samples, especially in combination with 
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environmental exposure data for outcomes as rare as individual birth defects, are not trivial. 
Collaborative projects such as the population-based NBDPS [85], funded by the US Centers 
for Disease Control and Prevention, and consortia such as GENEVA, funded by the National 




Knowledge gained from birth defects research allows women and their health care providers 
to make better informed decisions about exposures during pregnancy, leading to a reduction 
in the number of pregnancies affected by birth defects. However, demonstrating the public 
health impact of this research is challenging. There is no national system for reporting birth 
defects in the United States, and although there are birth defects surveillance systems in 41 
states [87], not all systems include all births in the state. States also may differ on other 
critical variables such as which defect categories are included, case definitions, and case 
verification methods. Although data from these systems can be pooled to estimate a 
“national prevalence” of selected birth defects [59], these estimates have large uncertainty 
due to variations in surveillance methodology (e.g., active versus passive ascertainment) and 
differences in clinical practice (e.g., higher or lower screening rates for certain defects).
Temporal trends in the prevalence of specific birth defects are influenced by multiple 
factors; a reduction in the prevalence of one risk factor may be offset by the increase of 
another. For example, the prevalence of cigarette smoking during pregnancy, a risk factor 
for certain birth defects, has decreased over time, from 18.4% in 1990 [88] to 12.3% in 2010 
[89]. However, the prevalence of obesity, another recognized risk factor for certain birth 
defects, has increased dramatically over time for reproductive-aged women, from 12.0% in 
1991 [90] to 35.7% in 2009-2010 [91].
Temporal trends can also occur among subgroups of the population, which can be obscured 
when the entire population is considered. For example, an increase in the prevalence of 
gastroschisis has been observed in the United States, from 2.3 to 4.4 per 10,000 live births in 
1995 and 2005 respectively; however, the absolute increase among women less than 20 
years old has been markedly higher, from approximately 8 per 10,000 to 15 per 10,000 
during the same time period [92].
Simulation modeling offers an opportunity to estimate the potential public health impact of 
reducing harmful exposures (or increasing beneficial ones), which may not be detectable 
using currently available surveillance data. Simulations have been used to estimate the 
number of cases of specific birth defects that could be prevented with decreased use of 
teratogenic antiepileptic medications [93]; a reduction in the prevalence of prepregnancy 
obesity [94]; elimination of periconceptional cigarette smoking [95]; addition of folic acid to 
birth control pills [96] and folic acid fortification of corn masa flour [97].
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Despite the challenges described above, research has been successful in identifying 
modifiable risk factors for birth defects leading to the implementation of effective 
prevention strategies [98]. However, the changing landscape of maternal exposures makes 
continued clinical, surveillance, and research vigilance necessary. For example, new 
medications enter the market every year, the vast majority of which have insufficient clinical 
or epidemiological data to determine teratogenic risk [99, 100]; in addition, existing 
medications may be approved for new indications or used off label for a wider range of 
conditions [101]. Further, although the prevalence of traditional smoking has decreased over 
time, the introduction and increasing use of the e-cigarette may increase the exposure to 
nicotine during pregnancy [102].
Conclusion
Current research methods do not allow for the definitive assertion of the safety of an 
exposure during pregnancy; we can never rule out all risk for all pregnancies. The number of 
prenatal exposures for which we are able to quantify the associated risk for birth defects is 
small compared to the vast number of substances and experiences to which a pregnant 
woman can be exposed. However, well-conducted birth defects research provides 
information to pregnant women and their healthcare providers that allow them to reduce the 
risk for birth defects. In addition, this information can serve to lessen worry for women 
about necessary (e.g., medications) or accidental exposures during pregnancy, also a 
worthwhile outcome.
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